Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Lexaria Bioscience ( (LEXX) ) is now available.
Lexaria has outlined its 2026 research and development program, centering on new human and animal studies intended to expand pharmaceutical applications and intellectual property around its DehydraTECH drug delivery platform. Management emphasized that the program is designed to generate practical results that increase the likelihood of industry partnerships and new patentable formulations, particularly in the GLP-1 and cannabidiol therapeutic categories.
The flagship human trial, GLP-1-H26-7, will compare SNAC-inclusive DehydraTECH-semaglutide capsules and tablets with commercially available Wegovy tablets over a five-week period, with a larger sample size aimed at producing statistically robust pharmacokinetic and safety data by late 2026. In parallel, two animal studies, including GLP-1-A26-1 with multiple dosing arms and brain biodistribution assessments, will test a range of GLP-1 and cannabidiol formulations to support new IP generation and refine candidates for future human trials, potentially strengthening Lexaria’s position in next-generation metabolic and neurological treatments.
The most recent analyst rating on (LEXX) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Lexaria Bioscience stock, see the LEXX Stock Forecast page.
More about Lexaria Bioscience
Lexaria Bioscience Corp. is a drug delivery technology company that develops and commercializes its DehydraTECH platform to enhance the absorption and effectiveness of active pharmaceutical ingredients. The company focuses on applications in GLP-1 therapies, cannabidiol-based therapeutics, and other pharma partnerships, targeting improved formulations that can attract licensing and co-development deals.
Average Trading Volume: 643,774
Technical Sentiment Signal: Sell
Current Market Cap: $16.8M
For detailed information about LEXX stock, go to TipRanks’ Stock Analysis page.